Piramal Pharma renforce ses opérations prêtes pour l'avenir avec une réduction de 22,6 % des émissions, 41 % des énergies renouvelables et « zéro observation » de l'OAI par la FDA américaine

RegulatoryPositive

AI Analysis

Summary

Piramal Pharma Limited announced a 22.6% reduction in Scope 1 and 2 emissions, 41% renewable energy usage, and zero observations from FDA inspections. The company achieved record-low emissions as part of its SBTi-approved decarbonization journey.

Outcome Details

Zero observations from FDA OAI (Other Authorized Inspectors)

Importance:3/10

Sentiment:

0.70

sustainabilityemissions_reductionrenewable_energyFDA_inspectionESGdecarbonization

Read the original article

Published by PR Newswire Pharma on August 27, 2026 11:43 AM

Read Original